الإحصائيات الأساسية
| LEI | 5299003IE70ITO2CBM73 |
| CIK | 1211583 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fennec Pharmaceuticals Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 14, 2025 |
Press Release for Quarter June 30, 2025 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over- Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient S |
|
| August 14, 2025 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents . UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 14, 2025 |
Press Release for Quarter Ended March 31, 2024 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSIÒ Now Commercially Available in Germany and the United Kingdom ~ ~ Management to |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32 |
|
| March 26, 2025 |
Press Release for Fiscal Year Ended December 31, 2022 Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Continued Momentum in the Adolescent and Young Adult (AYA) Segment and Academic Setting Following Strategic Investmen |
|
| March 26, 2025 |
Form of Restricted Stock Award Agreement under 2020 Equity Incentive Plan* EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE FENNEC PHARMACEUTICALS INC. |
|
| March 26, 2025 |
Form of Stock Option Award Agreement under 2020 Equity Incentive Plan* INCENTIVE STOCK OPTION AGREEMENT UNDER THE FENNEC PHARMACEUTICAL INC. 2020 EQUITY INCENTIVE PLAN FIRSTNAME LASTNAME ADDRESSLINE1 ADDRESSLINE2 CITY - STATE ZIPCODE COUNTRY Grant Number Pursuant to the Fennec Pharmaceuticals Inc. 2020 Equity Incentive Plan as amended through the date hereof (the “Plan”), Fennec Pharmaceuticals Inc. (the “Company”) hereby grants to the Optionee named above an option |
|
| March 10, 2025 |
Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term |
|
| March 10, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| February 14, 2025 |
Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares of Fennec Pharmaceuticals Inc. |
|
| February 7, 2025 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF PEDMARQSIÒ IN GERMANY ~ PEDMARQSI Ò is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with Localized, Non-Metastatic Solid Tumors ~ ~ Norgine Pharmaceuticals’ Launch of PEDMARQSIÒ in Germany Accelera |
|
| February 7, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| December 20, 2024 |
Exhibit 10.1 WAIVER AND REDEMPTION AGREEMENT This Waiver and Redemption Agreement, dated as of December 18, 2024 (this “Agreement”), is entered into by and among Fennec Pharmaceuticals, Inc., a British Columbia corporation (the “Company”), the investors party hereto (the “Investors”), and Petrichor Opportunities Fund I LP, as collateral agent (in such capacity, the “Collateral Agent”; and together |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| December 20, 2024 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES PEDMARQSIÒ POSITIVE RECOMMENDATION BY NICE FOR THE PREVENTION OF CISPLATIN-INDUCED HEARING LOSS IN ENGLAND AND WALES ~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) |
|
| December 20, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| December 20, 2024 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT ~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ Research Triangle Park, NC, December 1 |
|
| November 12, 2024 |
FENC / Fennec Pharmaceuticals Inc. / DG Capital Management, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* FENNEC PHARMACEUTICALS INC. Common Shares (Title of Class of Securities) 31447P100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| November 8, 2024 |
Press Release for Quarter Ended September 30, 2024 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARKÒ ~ ~ Strengthened Executive Leadershi |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 30, 2024 |
Exhibit 99.1 Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth ~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., October 28, 2024 – Fennec Pharmaceuticals I |
|
| October 30, 2024 |
Executive Employment Agreement between the Company and Terry Evans, effective as of October 28, 2024 Exhibit 10.2 October , 2024 Dear Terry Evans (“Executive”): On behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Commercial Officer. The purpose of this agreement is to clarify the terms of Executive’s “at will” employment with the Company, including Executive’s compensat |
|
| October 30, 2024 |
Exhibit 10.3 October , 2024 Dear Christiana Cioffi (“Executive”): On behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Strategy Officer. The purpose of this agreement is to clarify the terms of Executive’s “at will” employment with the Company, including Executive’s compensatio |
|
| October 30, 2024 |
Exhibit 10.1 October , 2024 Dear Pierre Sayad (“Executive”): On behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Medical Officer. The purpose of this agreement is to clarify the terms of Executive’s “at will” employment with the Company, including Executive’s compensation leve |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 13, 2024 |
Press Release for Quarter Ended June 30, 2024 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Co |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| August 7, 2024 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT THIS CONFIDENTIAL SEPARATION AGREEMENT (the “Agreement”) is made and entered into on August , 2024 by and among Rostislav Raykov (the “Executive”) and Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec US”), Fennec Pharmaceuticals Inc., a British Columbia corporation (“Parent”) (Fennec US, Parent and their respective affiliated corporations |
|
| August 7, 2024 |
Exhibit 99.1 Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., August 5, 202 |
|
| August 7, 2024 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”) is entered into the 5th day of August, 2024 by and between FENNEC PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and JEFF HACKMAN (the “Executive”). WHEREAS the Company desires to employ the Executive in the capacity of full-time Chief Executive Officer pursuant to the terms of this Ag |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| July 2, 2024 |
FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE RESEARCH TRIANGLE PARK, N.C., July 1, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, A |
|
| July 2, 2024 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT THIS CONFIDENTIAL SEPARATION AGREEMENT (the “Agreement”) is made and entered into on June 30, 2024 by and among Adrian Haigh (the “Employee”), Fennec Pharmaceuticals (EU) Limited, Fennec Pharmaceuticals Inc. and their respective affiliated corporations, predecessors, and successors (collectively, the “Company”). The Employee and the Company are someti |
|
| June 27, 2024 |
FENC / Fennec Pharmaceuticals Inc. / DG Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 25, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 14, 2024 |
Press Release for Quarter Ended March 31, 2024 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved First Quarter 2024 Net Revenues of $25.4 Million including $18.0 million in licensing revenue from Norgine transaction ~ ~Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARKÒ Permanent J-code 0 |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 9, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other j |
|
| May 9, 2024 |
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 Exhibit 99.1 Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 RESEARCH TRIANGLE PARK, N.C., May 7, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, Ma |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32 |
|
| March 29, 2024 |
Fennec Pharmaceuticals, Inc. Incentive Compensation Recovery Policy Exhibit 97 FENNEC PHARMACEUTICALS INC. Compensation Recovery Policy Policy Overview The purpose of this Compensation Recovery Policy (this “Policy”) of Fennec Pharmaceuticals Inc. (the “Company”) is to provide for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under United States |
|
| March 29, 2024 |
Fennec Pharmaceuticlas, Inc. Description of the Registrant’s Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary of the terms of Fennec Pharmaceuticals Inc.’s capital stock does not purport to be complete and is subject to and qualified in its entirety by reference to our Notice of Articles and Articles, each of which may be further amended from time to time an |
|
| March 29, 2024 |
Fennec Pharmaceuticals, Inc. Insider Trading Policy, dated July 11, 2009. Exhibit 10.16 STATEMENT of POLICY and PROCEDURE Chapter: Financial SPP No. FI 2.01.4 Section: Issued: July 11, 2009 Subject: INSIDER TRADING Effective: July 11, 2009 Issue to: All Manual Holders Page: 1 of 11 Replaces: FI 2.01.3 Issued by: Compliance Officer Dated: August 30, 2004 1 POLICY 1.01 In General Directors, officers and other employees of Fennec Pharmaceuticals Inc. (“Fennec”) will often |
|
| March 29, 2024 |
Press Release for Fiscal Year Ended December 31, 2022 Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved PEDMARKÒ Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSIÔ in Europe, Australia and New Zealand for Approximately |
|
| March 25, 2024 |
Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately |
|
| March 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| March 21, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| March 21, 2024 |
Exhibit 99.1 Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with lo |
|
| March 21, 2024 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN REDACTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. [***] INDICATES INFORMATION HAS BEEN REDACTED. EXECUTION VERSION LICENSE AND SUPPLY AGREEMENT THIS LICENSE AND SUPPLY AGREEMENT (the “Agreement”) is entered into as of 15 March, 2024 (the “Effective Date”) by and between |
|
| March 15, 2024 |
FENNEC PHARMACEUTICALS INC. Up to 760,456 of Common Shares FILED PURSUANT TO RULE 424(B)(7) REGISTRATION NO.: 333-275452 PROSPECTUS SUPPLEMENT (To Prospectus dated December 15, 2023) FENNEC PHARMACEUTICALS INC. Up to 760,456 of Common Shares This prospectus supplement and the accompanying prospectus relates to the possible resale of up to 760,456 of our common shares, no par value per share, from time to time in one or more offerings by the selling stockh |
|
| March 6, 2024 |
Exhibit 99.1 Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results ~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., February 29, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; T |
|
| March 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20 |
|
| February 29, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| February 29, 2024 |
Exhibit 99.1 Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results ~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE PARK, N.C., February 29, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; T |
|
| February 14, 2024 |
FENC / Fennec Pharmaceuticals Inc. / Solas Capital Management, LLC Passive Investment SC 13G 1 fenc13g2024v3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Fennec Pharmaceuticals Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 2, 2024 |
Exhibit 99.1 FDA Issues Reminder of Non-Substitution of PEDMARKÒ (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin RESEARCH TRIANGLE PARK, N.C., February 1, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthca |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| December 13, 2023 |
Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709 December 13, 2023 Via EDGAR Correspondence Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington D. C. 20549 Re: Acceleration of Effective Date Fennec Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-275452 Ladies a |
|
| December 6, 2023 |
First Amendment to the Securities Purchase Agreement Exhibit 10.1 FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT This FIRST AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT (this “First Amendment”) is dated as of December 4, 2023 and is made in reference to that certain Securities Purchase Agreement, dated as of August 1, 2022 (as may be amended, restated or otherwise modified from time to time, the “Purchase Agreement”), by and among Fennec P |
|
| December 6, 2023 |
Exhibit 99.1 FENNEC ANNOUNCES INCREMENTAL $5 MILLION INVESTMENT FROM PETRICHOR ~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion into the Adolescent and Young Adult (AYA) Patient Population ~ Research Triangle Park, NC, December 5, 2023 – Fennec Pharmaceuticals Inc |
|
| December 6, 2023 |
Exhibit 4.1 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUAN |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| November 9, 2023 |
Press Release for Quarter Ended September 30, 2023 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~Received Approval in October 2023 by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for PEDMAR |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration Statement No. |
|
| November 9, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Fennec Pharmaceuticals Inc. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2023 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 2023 by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for PEDMA |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| August 7, 2023 |
Press Release for Quarter Ended June 30, 2023 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Growing Physician Awareness and Usage of PEDMARK® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research Triangle Park, NC, August 3 |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| August 7, 2023 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Growing Physician Awareness and Usage of PEDMARK® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research Triangle Park, NC, August 3 |
|
| August 7, 2023 |
Employment Agreement Adrian Haigh Exhibit 10.1 August 3, 2023 Dear Adrian On behalf of the Board of Directors of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join Fennec Pharmaceuticals EU Limited, a wholly owned subsidiary of Fennec, as its Chief Operating Officer (“COO”). The purpose of this agreement is to clarify the terms of Employee’s “at will” employment with the C |
|
| August 4, 2023 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Growing Physician Awareness and Usage of PEDMARK® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research Triangle Park, NC, August 3 |
|
| August 4, 2023 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Growing Physician Awareness and Usage of PEDMARK® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research Triangle Park, NC, August 3 |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| August 4, 2023 |
Employment Agreement Adrian Haigh Exhibit 10.1 August 3, 2023 Dear Adrian On behalf of the Board of Directors of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join Fennec Pharmaceuticals EU Limited, a wholly owned subsidiary of Fennec, as its Chief Operating Officer (“COO”). The purpose of this agreement is to clarify the terms of Employee’s “at will” employment with the C |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| June 13, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 7, 2023 |
Exhibit 99.1 Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients ~ Pedmarqsi™ is the First and Only Approved Therapy in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumor |
|
| June 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 12, 2023 |
Press Release for Quarter Ended March 31, 2022 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Strong PEDMARK® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~PEDMARK® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU Recommending Approval of PEDMARQSITM ~ ~ Company to Host Conference Call Today, Thursday, May 11 at 8: |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| April 4, 2023 |
Exhibit 99.1 Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients ~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based o |
|
| March 29, 2023 |
Press Release for Fiscal Year Ended December 31, 2022 Exhibit 99.1 FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2022 FINANCIAL RESULTS ~ U.S. Commercial Team in Place with PEDMARK® Launch Off to Solid Start Following FDA Approval of PEDMARK® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ Research Triangle Park, NC, March 30, 2023 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32 |
|
| February 14, 2023 |
FENC / Fennec Pharmaceuticals Inc. / Sonic GP LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Fennec Pharmaceuticals Inc. (Name of Issuer) Common stock, no par value (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2022 (Date of Event w |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| January 31, 2023 |
Exhibit 99.1 Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA ~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PE |
|
| January 25, 2023 |
Exhibit 99.1 Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumor |
|
| January 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| December 15, 2022 |
Fennec Pharmaceuticals Inc. 3,914,850 Common Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-268632 PROSPECTUS Fennec Pharmaceuticals Inc. 3,914,850 Common Shares This prospectus relates to the possible resale of up to 3,914,850 of our common shares, no par value per share, from time to time in one or more offerings by the selling stockholder named herein. Of the 3,914,850 common shares offered for resale by the selling stockholder und |
|
| December 8, 2022 |
CORRESP 1 filename1.htm Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709 December 8, 2022 Via EDGAR Correspondence Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington D. C. 20549 Re: Acceleration of Effective Date Fennec Pharmaceuticals Inc. Registration Statement on Form S-3 File |
|
| December 1, 2022 |
Exhibit 4.7 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO |
|
| December 1, 2022 |
Exhibit 4.6 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO |
|
| December 1, 2022 |
Exhibit 4.8 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A |
|
| December 1, 2022 |
As filed with the Securities and Exchange Commission on December 1, 2022 As filed with the Securities and Exchange Commission on December 1, 2022 Registration Statement No. |
|
| December 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) FENNEC PHARMACEUTICALS INC. |
|
| December 1, 2022 |
Exhibit 4.5 ? SPA-EXECUTION VERSION SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of August 1, 2022, by and among Fennec Pharmaceuticals Inc., a British Columbia corporation (the ?Company?), each investor identified on the signature pages hereto (each, an ?Investor? and collectively, the ?Investors?), and Petrichor Opportunities Fund I LP, as collate |
|
| December 1, 2022 |
Exhibit 4.9 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY U.S. STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM A |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 14, 2022 |
Press Release for Quarter Ended September 30, 2022 (filed herewith). Exhibit 99.1 ? ? FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ? ~ In September 2022, FDA Approved PEDMARK?, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ? ~ Initiated U.S. Commercial Launch of PEDMARK? in October 2022 ~ |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| October 17, 2022 |
Exhibit 99.1 Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK? (sodium thiosulfate injection) in the United States ~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients ~ ~ Fennec HEARS? Program Offers Comprehensive Patient Services, Including Access to Care Coordinators, Financial and Prescripti |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or |
|
| September 26, 2022 |
Form of Second Closing Note and Form of Second Warrant Exhibit 4.1 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO |
|
| September 26, 2022 |
? ? ? ? Exhibit 99.1 ? FENNEC PHARMACEUTICALS ANNOUNCES SECOND CLOSING OF $20 MILLION INVESTMENT FROM PETRICHOR ? ~Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK? Which Occurred on September 20, 2022 ~ ? ~ Fennec Has the Potential to Access |
|
| September 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or |
|
| September 21, 2022 |
Exhibit 99.1 Fennec Pharmaceuticals Announces FDA Approval of PEDMARK? (Sodium Thiosulfate Injection) ~ PEDMARK? is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) - Fennec Pharmaceuticals Inc. (NASDAQ: FENC; |
|
| August 22, 2022 |
? ? ? ? Exhibit 99.1 ? FENNEC PHARMACEUTICALS CLOSES FIRST $5 MILLION INVESTMENT FROM PETRICHOR ? ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ? ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ ? Research Triangle Park, NC, August 22, 2022 |
|
| August 22, 2022 |
Form of First Closing Note and Form of First Warrant Exhibit 4.1 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO |
|
| August 22, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or |
|
| August 12, 2022 |
Press Release for Quarter Ended June 30, 2022 (filed herewith). Exhibit 99.1 ? ? FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ? ~ PEDMARK FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ? ~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~ ? ~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S. Commerc |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 1, 2022 |
Exhibit 10.1 ? SPA-EXECUTION VERSION ? SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of August 1, 2022, by and among Fennec Pharmaceuticals Inc., a British Columbia corporation (the ?Company?), each investor identified on the signature pages hereto (each, an ?Investor? and collectively, the ?Investors?), and Petrichor Opportunities Fund I LP, as coll |
|
| August 1, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or |
|
| August 1, 2022 |
? ? ? ? Exhibit 99.1 ? ? Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ ~ Funding to Support the Potential Commercia |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 12, 2022 |
Press Release for Quarter Ended March 31, 2022 (filed herewith). Exhibit 99.1 ? ? FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ? ~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ? ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ? ~ Company Has Approximately $18.3 Million in Cash a |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 2, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6( |
|
| March 24, 2022 |
Exhibit 99.1 FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINSTRATION FOR PEDMARKTM Research Triangle Park, NC, March 24, 2022 ? Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique formulation |
|
| March 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| February 28, 2022 |
Press Release for Fiscal Year Ended December 31, 2020 Exhibit 99.1 ? ? FENNEC PHARMACEUTICALS ANNOUNCES FISCAL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ? ? ~ Resubmission of NDA for PEDMARKTM Targeted for the First Quarter of 2022 ~ ? ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded Debt ~ ? Research Triangle Park, NC, February 28, 2022 ? Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharma |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 31447P100 (CUSIP Number) |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| January 31, 2022 |
FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE Research Triangle Park, NC, Jan. 31, 2022 ? Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Shubh Goel, the Company? |
|
| January 31, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2022 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| January 31, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO THE LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to the Loan and Security Agreement (this ?Amendment?) is made effective as of January 27, 2022 (the ?Amendment Date?) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Bank?) and FENNEC PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?). WHEREAS, Bank and Borrower have entered into that |
|
| November 30, 2021 |
Exhibit 99.1 Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK? to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors RESEARCH TRIANGLE PARK, N.C., November 30, 2021 ? Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete |
|
| November 30, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| November 29, 2021 |
Exhibit 99.1 Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK? to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors ~ FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK A |
|
| November 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 10, 2021 |
Press Release for Quarter Ended September 30, 2021 (filed herewith). Exhibit 99.1 ? ? FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ? ~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ? ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ? ~ Company Has Approximately $24 Million in Cash and |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 10, 2021 |
Press Release for Quarter Ended June 30, 2021 (filed herewith). Exhibit 99.1 ? ? FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ? ~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ? ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ? ~ Company Has Approximately $27 Million in Cash and |
|
| June 30, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 24, 2021 |
Exhibit 10.1 SECOND AMENDMENT TO THE LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to the Loan and Security Agreement (this ?Amendment?) is made effective as of June 21, 2021 (the ?Amendment Date?) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (?Bank?) and FENNEC PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?). WHEREAS, Bank and Borrower have entered into that |
|
| June 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 24, 2021 |
FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Research Triangle Park, NC, June 24, 2021 ? Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients with localiz |
|
| June 22, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 22, 2021 |
Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION RESUBMISSION FOR PEDMARKTM ~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~ ~ NDA Resubmission for PEDMARK for the Prevention of Cisplatin-Induced Ototoxicity for Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ If Approved by the FDA, PEDMARK Stands to Be t |
|
| May 28, 2021 |
Exhibit 99.1 FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARKTM ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ Research Triangle Park, NC, May 28, 2021 ? Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced t |
|
| May 28, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box ? Preliminary Proxy Statement x Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material P |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PH |
|
| May 13, 2021 |
Press Release for Quarter Ended March 31, 2021 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK? to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~ ~ Company Has Approximately $27 Million in Cash and No Outstanding Debt ~ Research Triangle Park, NC, May 13, 2021 ? Fennec Ph |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHARMAC |
|
| March 30, 2021 |
Press Release for Fiscal Year Ended December 31, 2020 Exhibit 99.1 FENNEC ANNOUNCES FISCAL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK? ~ ~ Resubmission of the NDA for PEDMARKTM is Planned for the Second Quarter of 2021 ~ ~ Company Has Approximately $30 Million in Cash and No Outstanding Debt ~ Re |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 31447P100 (CUSIP Number) A |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 12, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| November 16, 2020 |
Press Release for Quarter Ended September 30, 2020 (filed herewith). Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARKTM ~ ~ No Clinical Safety or Efficacy Issues Identified; No Additional Studies Required for PEDMARKTM ~ ~ The Company Has Approximately |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNE |
|
| November 6, 2020 |
Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709 November 6, 2020 Via EDGAR Correspondence Jeffrey Gabor Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F. Street, N.E. Washington D. C. 20549 Re: Acceleration of Effective Date Fennec Pharmaceuticals Inc. Registration Statement on Form S-3 File No. 333-24 |
|
| October 30, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| October 30, 2020 |
FENNEC PHARMACEUTICALS INC. Up to $25,000,000 of Common Shares TABLE OF CONTENTS FILED PURSUANT TO RULE 424(B)(5) REGISTRATION NO.: 333-221093 PROSPECTUS SUPPLEMENT (To Prospectus dated November 3, 2017) FENNEC PHARMACEUTICALS INC. Up to $25,000,000 of Common Shares This prospectus supplement and the accompanying prospectus relate to the offer and sale from time to time of shares of our common shares, no par value per share (our “common shares”), having an |
|
| October 30, 2020 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT October 30, 2020 H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: Fennec Pharmaceuticals Inc., a British Columbia corporation (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in this Agreement and any |
|
| October 30, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 30, 2020 Registration Statement No. |
|
| September 21, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or |
|
| September 21, 2020 |
FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR PEDMARKTM EX-99.1 2 tm2031405d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR PEDMARKTM Research Triangle Park, NC, September 21, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pedi |
|
| August 11, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or oth |
|
| August 11, 2020 |
Exhibit 99.1 Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors ~ No Clinical Safety or Efficacy Issues Identified, and No Requirement for Further Clinical Data ~ ~ FDA Pre-Approval Inspection has Identified Deficiencies wi |
|
| August 5, 2020 |
Press Release for Quarter Ended June 30, 2020 (filed herewith). EX-99.1 5 tm2020447d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Strong Financial Position with $38.7 million in cash and no debt ~ Research Triangle Park, NC, August 5, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a s |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHA |
|
| June 26, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 26, 2020 |
FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES AMENDMENT TO INCREASE EXISTING SENIOR DEBT FACILITY Research Triangle Park, NC, June 26, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today annou |
|
| June 26, 2020 |
EX-10.1 2 tm2023488d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO THE LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to the Loan and Security Agreement (this “Amendment”) is made effective as of June 25, 2020 (the “Amendment Date”) and made by and among WESTERN ALLIANCE BANK, an Arizona corporation (“Bank”) and FENNEC PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”). WHEREAS |
|
| June 23, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 14, 2020 |
Press Release for Quarter Ended March 31, 2020 (filed herewith). EX-99.1 5 tm2014617d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ FDA Set a PDUFA Target Action Date for PEDMARKTM of August 10, 2020 ~ ~ Marketing Authorization Application (MAA) Validated by the EMA in February 2020 ~ ~ Strengthened its Financial Position Through a Raise of Approximately $32 Million in N |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PH |
|
| May 11, 2020 |
our Definitive Proxy Statement on Schedule 14A filed with the SEC on May 11, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box ¨ Preliminary Proxy Statement x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material P |
|
| May 4, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (AMENDMENT NO. 1) Under the Securities Exchange Act of 1934 Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 31447P100 (CUSIP Number) Marino Zigrossi Managing Director Essetifin S.p.A. Via Sudafrica, 20 Rome, RM 00144 Italy +39 06 5427711 (Name, Address and Telephone Number |
|
| May 4, 2020 |
EX-1.1 2 tm2017919d3ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 FENNEC PHARMACEUTICALS INC. 4,800,000 Common Shares, no par value Underwriting Agreement April 30, 2020 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Fennec Pharmaceuticals Inc., a British Columbia corporation |
|
| May 4, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| May 4, 2020 |
Fennec Announces Pricing of Public Offering EX-99.2 5 tm2017919d3ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Fennec Announces Pricing of Public Offering Research Triangle Park, N.C., April 30, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric |
|
| May 4, 2020 |
Fennec Announces Proposed Public Offering of Common Shares Exhibit 99.1 Fennec Announces Proposed Public Offering of Common Shares Research Triangle Park, N.C., April 29, 2020 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announ |
|
| May 1, 2020 |
4,800,000 Shares FENNEC PHARMACEUTICALS INC. Common Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-221093 PROSPECTUS SUPPLEMENT (To the Prospectus dated November 3, 2017) 4,800,000 Shares FENNEC PHARMACEUTICALS INC. Common Shares We are offering 4,800,000 of our common shares, no par value per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common shares are listed on The Nasda |
|
| April 29, 2020 |
SUBJECT TO COMPLETION, DATED APRIL 29, 2020 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| April 13, 2020 |
EX-99.1 2 tm2015804d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES FDA FILING ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR PEDMARKTM ~ Potential for PEDMARK to be the First Product for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ FDA Grants Priority Review and Sets a Prescription Drug User Fee Act (PDUFA) Target Action Date of August 10, 20 |
|
| April 13, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| March 5, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| March 5, 2020 |
FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARKTM EX-99.1 2 tm2011845d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC ANNOUNCES ISSUANCE OF U.S. PATENT FOR USE OF PEDMARKTM Research Triangle Park, NC, March 5, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pe |
|
| February 28, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| February 28, 2020 |
Exhibit 99.1 Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate Potential First Product in Europe for the Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 28, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that t |
|
| February 14, 2020 |
Press Release for Fiscal Year Ended December 31, 2019 EX-99.1 7 tm205262d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in the second half of 2020 Solid financial position with $13.7 mi |
|
| February 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| February 14, 2020 |
our Annual Report on Form 10-K for the year ended December 31, 2019; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHARMAC |
|
| February 14, 2020 |
EX-99.1 2 tm207990d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2019 FINANCIAL RESULTS NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in the second half of 2020 Solid financial position with $13.7 mi |
|
| February 14, 2020 |
Exhibit 21 to the 10-K of the Company filed February 14, 2020 EX-21 2 tm205262d1ex21.htm EXHIBIT 21 EXHIBIT 21 Fennec Pharmaceuticals Inc. Subsidiaries Oxiquant, Inc., a Delaware corporation Fennec Pharmaceuticals, Inc., a Delaware corporation Cadherin Biomedical Inc., a Canadian corporation Fennec Pharmaceuticals (EU) Limited, an Irish Private Company Limited by Shares |
|
| February 11, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2020 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| February 11, 2020 |
EX-99.1 2 tm207410d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDMARKTM AND ALSO SUBMITS MARKETING AUTHORIZATION APPLICATION (MAA) TO EUROPEAN MEDICINES AGENCY PEDMARKTM1 is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| November 12, 2019 |
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS · NDA (New Drug Application) for PEDMARKTM to be completed in early 2020 · Strong financial position with $15.2 million in cash and no debt Research Triangle Park, NC, November 12, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development o |
|
| November 12, 2019 |
Press Release for Quarter Ended September 30, 2019 (filed herewith). Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS · NDA (New Drug Application) for PEDMARKTM to be completed in early 2020 · Strong financial position with $15.2 million in cash and no debt Research Triangle Park, NC, November 12, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development o |
|
| November 12, 2019 |
FENC / Fennec Pharmaceuticals Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNE |
|
| September 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or |
|
| September 24, 2019 |
FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS EX-99.1 2 tv530001ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS Research Triangle Park, NC, September 24, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in ped |
|
| September 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or o |
|
| September 9, 2019 |
EX-99.1 3 tv529087ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER Seasoned commercial leader to lead the anticipated launch of PEDMARKTM Research Triangle Park, NC, September 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate |
|
| September 9, 2019 |
Executive Employment Agreement of Shubh Goel EX-10.1 2 tv529087ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 September , 2019 Dear Shubh Goel (“Employee”): On behalf of the Board of Directors of Fennec Pharmaceuticals, Inc. (“Fennec” or the “Company”), I am pleased to make you an executable offer to join the Company as its Chief Commercial Officer. The purpose of this agreement is to clarify the terms of Employee’s “at will” employment with the Compa |
|
| August 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| August 9, 2019 |
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS · Anticipate PEDMARKTM New Drug Application (NDA) completion by early 2020 · Strong financial position with $17.5 million in cash and no debt Research Triangle Park, NC, August 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development o |
|
| August 9, 2019 |
Press Release for Quarter Ended June 30, 2019 (filed herewith). Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS · Anticipate PEDMARKTM New Drug Application (NDA) completion by early 2020 · Strong financial position with $17.5 million in cash and no debt Research Triangle Park, NC, August 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development o |
|
| August 9, 2019 |
FENC / Fennec Pharmaceuticals Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHA |
|
| June 26, 2019 |
FENC / Fennec Pharmaceuticals Inc. S-8 - - FORM S-8 Registration No. 333- As filed with the Securities and Exchange Commission on June 26, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada (State or Other Jurisdiction of Incorporation or Organization) 20 |
|
| June 20, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 20, 2019 |
Fennec Pharmaceuticals Inc. Amended and Restated Stock Option Plan (as amended on June 18, 2019). Exhibit 10.1 FENNEC PHARMACEUTICALS INC. AMENDED AND RESTATED STOCK OPTION PLAN PLAN DESCRIPTION 1. Purpose of the Plan The purpose of the Fennec Pharmaceuticals Inc. Amended and Restated Stock Option Plan is to develop the interest and incentive of eligible employees, directors and other service providers of FENNEC PHARMACEUTICALS INC. (the "Company"), in the Company's growth and development by p |
|
| May 16, 2019 |
FENC / Fennec Pharmaceuticals Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box ¨ Preliminary Proxy Statement x Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material P |
|
| May 10, 2019 |
FENC / Fennec Pharmaceuticals Inc. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PH |
|
| May 10, 2019 |
Press Release for Quarter Ended March 31, 2019 (filed herewith). Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS · Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 · Strong financial position with $20.2 million in cash and no debt Research Triangle Park, NC, May 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the develo |
|
| May 9, 2019 |
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS EX-99.1 2 tv521214ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS · Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 · Strong financial position with $20.2 million in cash and no debt Research Triangle Park, NC, May 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty ph |
|
| May 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other j |
|
| April 23, 2019 |
100 University Avenue, 8th floor EX-99.1 2 exhibit99-1.htm NOTICE OF THE MEETING AND RECORD DATE Exhibit 99.1 100 University Avenue, 8th floor Date: April 18, 2019 Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: FENNEC PHARMACEUTICALS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : |
|
| April 23, 2019 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Com |
|
| April 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| March 15, 2019 |
FENC / Fennec Pharmaceuticals Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHARMAC |
|
| March 15, 2019 |
Registration of Fennec Pharmaceuticals (EU) Limited EX-21.1 2 tv515201ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 |
|
| March 14, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or othe |
|
| March 14, 2019 |
EX-99.1 2 tv516205ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS · Initiated rolling New Drug Application to U.S. FDA for PEDMARKTM · Secured $12. 5 million debt financing to support a potential commercial launch · Strong financial position with $22.8 million in cash and no debt · Targeted commercial launch in 2020 Research Tri |
|
| February 14, 2019 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Fennec Pharmaceuticals Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 7)* Fennec Pharmaceuticals Inc. (formerly Adherex Technologies Inc.) (Name of Issuer) Common stock, no par value (Title of Class of Securities) 31447P100 (CUSIP Numbe |
|
| February 14, 2019 |
FENCF / Fennec Pharmaceuticals, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) FENNEC PHARMACEUTICALS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 31447P100 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 4, 2019 |
EX-10.1 2 tv512337ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FENNEC PHARMACEUTICALS, INC., A DELAWARE CORPORATION WESTERN ALLIANCE BANK, an arizona corporation LOAN AND SECURITY AGREEMENT This Loan And Security Agreement is entered into as of February 1, 2019 (the “Effective Date”), by and between Western Alliance Bank, an Arizona corporation (“Bank”) and Fennec Pharmaceuticals, INC., a Delaware corpora |
|
| February 4, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2019 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or ot |
|
| February 4, 2019 |
FENNEC PHARMACEUTICALS ANNOUNCES $12.5 MILLION DEBT FINANCING WITH BRIDGE BANK Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES $12.5 MILLION DEBT FINANCING WITH BRIDGE BANK Research Triangle Park, NC, February 4, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS) to be administered by infusion) for the prevention of ototoxicity induced by cispla |
|
| November 13, 2018 |
Press Release for Quarter Ended September 30, 2018 (filed herewith). Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS · Positive Opinion on the Pediatric Investigation Plan from EMA for PEDMARKTM · Targeting US approval of PEDMARKTM in the second half of 2019 · Strong financial position with $24.5 million in cash and no debt Research Triangle Park, NC, November 13, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: |
|
| November 13, 2018 |
FENC / Fennec Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNE |
|
| September 10, 2018 |
FENCF / Fennec Pharmaceuticals, Inc. / Manchester Management Pr, Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 17, 2018 |
FENCF / Fennec Pharmaceuticals, Inc. / Manchester Management Pr, Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 13, 2018 |
FENC / Fennec Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PHA |
|
| August 13, 2018 |
Press Release for Quarter Ended June 30, 2018 (filed herewith). Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS · Publication of PEDMARKTM SIOPEL 6 Clinical Data in The New England Journal of Medicine · Joined Russell 3000 Index · Strong financial position with $25.6 million in cash and no debt Research Triangle Park, NC, August 13, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmace |
|
| June 27, 2018 |
FENCF / Fennec Pharmaceuticals, Inc. / Manchester Management Pr, Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| June 22, 2018 |
FENCF / Fennec Pharmaceuticals, Inc. / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 FENNEC PHARMACEUTICALS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 31447P100 (CUSIP Number) June 13, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| June 11, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| June 11, 2018 |
Fennec Pharmaceuticals Set to Join Russell 3000 Index Exhibit 99.1 Fennec Pharmaceuticals Set to Join Russell 3000 Index Research Triangle Park, NC, June 11, 2018 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC, TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today it is set to join t |
|
| June 11, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2018 FENNEC PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) 001-32295 (Commission File Number) British Columbia, Canada 20-0442384 (State or other |
|
| May 18, 2018 |
FENCF / Fennec Pharmaceuticals, Inc. / Manchester Management Pr, Llc Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32295 FENNEC PH |
|
| May 14, 2018 |
Press Release for Quarter Ended March 31, 2018 (filed herewith). EX-99.1 5 tv493283ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS · PEDMARKTM granted Breakthrough Therapy and Fast Track Designations by FDA · Actively preparing for NDA submission later this year · Strong financial position with $26.7 million in cash and no debt Research Triangle Park, NC, May 14, 2018 – Fennec Pharmaceutica |
